INmune completes first cohort, initiates second of Phase 1/2 study of INKmune

INmune Bio continues to advance its Natural Killer cell therapy, INKmune, in a Phase I/II trial for men with metastatic castration-resistant prostate cancer. The Company is pleased to announce the successful completion of the first cohort in the trial. Following review by the Safety Review Committee, approval has been granted to proceed with the second dose level. The first patient of the second cohort has been identified and will undergo screening to prepare for treatment. So far, there have been 9 administrations of INKmune in the mCRPC study given as an out-patient with no significant adverse events. When added to the experience with INKmune given in the MDS/AML trial, over 20 infusions of INKmune have been given safely without the need for conditioning therapy, pre-medication, or cytokine support.